The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Sigvotatug vedotin (SV), an investigational integrin beta-6 (IB6)–directed antibody?drug conjugate (ADC), and pembrolizumab combination therapy: Initial results from an ongoing phase 1 study (SGNB6A-001).
 
Kartik Sehgal
Honoraria - Academy for Continued Health Sciences; AmerisourceBergen; Binacea; Medscape; Pri-Med
Consulting or Advisory Role - Equinox Group; Exelixis; Guidepoint Global; Medscape; Pfizer; Scholar Rock
Research Funding - Merck (Inst)
Travel, Accommodations, Expenses - Binacea; Merck; Pfizer; Pri-Med
 
Jesus Corral Jaime
No Relationships to Disclose
 
Steven Powell
Consulting or Advisory Role - Bristol-Myers Squibb (Inst)
Speakers' Bureau - Alkermes (Inst)
Research Funding - Actuate Therapeutics (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); Incyte (Inst); Janssen Research & Development (Inst); Merck Sharp & Dohme (Inst); Molecular Templates (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst); Sensei Biotherapeutics (Inst); Sorrento Therapeutics (Inst); Takeda (Inst); Vyriad (Inst)
 
Cesar Augusto Perez
Consulting or Advisory Role - BeiGene; EMD Serono; Pfizer
Research Funding - Accutar Biotech (Inst); ADANATE Biotechnology (Inst); Artios (Inst); BeiGene (Inst); Coherent Biopharma (Inst); Compass Therapeutics (Inst); Corvus Pharmaceuticals (Inst); DualityBio (Inst); Elevation Oncology (Inst); Elpiscience (Inst); Genentech (Inst); Hyamab (Inst); Kinnate Biopharma (Inst); Kura Oncology (Inst); Loxo/Lilly (Inst); Merus (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Pierre Fabre (Inst); Relay Therapeutics (Inst); Ribon Therapeutics (Inst); Seagen (Inst); Systimmune (Inst); Tachyon Therapeutics (Inst); Tallac Therapeutics (Inst); Xilio Therapeutics (Inst); Zhuhai Yufan Biotechnologies (Inst)
 
Elisa Fontana
Employment - HCA/Sarah Cannon
Leadership - European Organisation for Research and Treatment of Cancer (EORTC)
Consulting or Advisory Role - Astellas Pharma; Bicycle Therapeutics; BMS; Erasca, Inc; Pfizer
Research Funding - Acerta Pharma (Inst); ADC Therapeutics (Inst); Amgen (Inst); Arcus Biosciences (Inst); Artios (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Basilea (Inst); Bayer (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); BioNTech SE (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Carrick Therapeutics (Inst); CASI Pharmaceuticals (Inst); Clovis Oncology (Inst); Crescendo Biologics (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Ellipses Pharma (Inst); Erasca, Inc (Inst); Exelixis (Inst); Fore Biotherapeutics (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); HUTCHMED (Inst); Ignyta/Genentech/Roche (Inst); Immunocore (Inst); Immunomedics (Inst); Incyte (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Janssen (Inst); Jiangsu Hengrui Medicine (Inst); Kronos Bio (Inst); Lilly (Inst); Lupin Pharmaceuticals (Inst); Macrogenics (Inst); Menarini (Inst); Merck KGaA (Inst); Mereo Biopharma (Inst); Merus (Inst); Millenium Pharamceuticals (Inst); Nerviano Medical Sciences (Inst); Nurix (Inst); Oxford VacMedix (Inst); Pfizer (Inst); Plexxikon (Inst); PMV Pharma (Inst); QED Therapeutics (Inst); Relay Therapeutics (Inst); Repare Therapeutics (Inst); Ribon Therapeutics (Inst); Roche (Inst); Sapience Therapeutics (Inst); Seagen (Inst); SERVIER (Inst); Stemline Therapeutics (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Bicycle Therapeutics; Caris Life Sciences; Erasca, Inc; Repare Therapeutics; Sapience Therapeutics; Seagen
 
Ed Kingsley
Employment - US Oncology
Stock and Other Ownership Interests - Gilead Sciences
 
Federico Longo Munoz
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Lilly; MSD; Roche; Servier
Research Funding - MSD (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Lilly; MSD
 
Sarina Piha-Paul
Consulting or Advisory Role - CRC Oncology; Lilly
Research Funding - ABM (Inst); Alkermes (Inst); Aminex (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squib (Inst); Cancer Prevention Research Institute of Texas (CPRIT) (Inst); Chugai Pharma (Inst); Cullinan Oncology (Inst); Cyclacel (Inst); Daichi Sanko (Inst); ENB Therapeutics (Inst); Epigenetix (Inst); Genmab (Inst); Gilead Sciences (Inst); Immunity Bio, Inc. (Inst); Immunomedics (Inst); Incyte (Inst); Innovent Biologics (Inst); Jazz Pharmaceuticals (Inst); Johnson & Johnson/Janssen (Inst); Loxo (Inst); Medivation (Inst); Merck Sharp and Dohme Corp. (Inst); Nectin Therapeutics (Inst); NIH/NCI (Inst); NRG Oncology (Inst); Nurix (Inst); OncoNano Inc (Inst); Pfizer (Inst); Phanes Therapeutics (Inst); Pieris Pharmaceuticals (Inst); ProfoundBio (Inst); Puma Biotechnology (Inst); Purinomia (Inst); Replimune (Inst); Roche/Blueprint (Inst); Seagen (Inst); Strand Therapeutics, Inc. (Inst); Tallac Therapeutics, Inc. (Inst); Toragen Therapeutics, Inc. (Inst); TransThera Biosciences (Inst); ViroMissile, Inc. (Inst); Xencor (Inst)
 
Rachel Sanborn
Honoraria - Curio Science; Illumina; OncLive/MJH Life Sciences; Targeted Oncology
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; BeiGene; Boehringer Ingelheim; Daiichi Sankyo; G1 Therapeutics; GE Healthcare; Gilead Sciences; GlaxoSmithKline; IDEOlogy Health; Illumina; InhibRx; Janssen Oncology; Johnson & Johnson/Janssen; Lilly; Sanofi/Aventis
Research Funding - AstraZeneca; Bristol-Myers Squibb (Inst); Merck
 
Jonathan Hayman
Employment - Pfizer; Seagen
Stock and Other Ownership Interests - Pfizer; Seagen
Research Funding - Pfizer; Seagen
 
Francesca Toffalorio
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Tianhua Wang
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Wyatt Chafin
Employment - Pfizer; Seagen
Stock and Other Ownership Interests - Pfizer; Seagen
Research Funding - Pfizer; Seagen
 
Solange Peters
Honoraria - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Ecancer (Inst); Ecancer (Inst); Fishawack Facilitate (Inst); Foundation Medicine (Inst); GlaxoSmithKline; Illumina (Inst); Imedex (Inst); Incyte (Inst); Ipsen (Inst); medscape (Inst); Medtoday (Inst); Mirati Therapeutics (Inst); MSD (Inst); Novartis (Inst); OncologyEducation (Inst); Peerview (Inst); PER (Inst); Pfizer (Inst); Prime Oncology (Inst); Research to Practice (Inst); RMEI Medical Education (Inst); Roche (Inst); Sanofi (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst)
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Biocartis (Inst); Bioinvent (Inst); BioNTech SE (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); F-Star Biotechnology (Inst); Foundation Medicine (Inst); Genzyme (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); HUTCHMED (Inst); Illumina (Inst); Incyte (Inst); Ipsen (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Novocure (Inst); Nuvation Bio (Inst); Nykode Therapeutics (Inst); Nykode Therapeutics (Inst); Pfizer (Inst); PharmaMar (Inst); Promontory Therapeutics (Inst); Qlucore (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Takeda (Inst); Vaccibody (Inst); Zymeworks (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Biodesix (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Illumina (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Incyte; MSD; Roche; Sanofi
(OPTIONAL) Uncompensated Relationships - Annals of Oncology (I); ESMO; ETOP Scientific chair; JTO Past Deputy Editor; SAMO President